Downregulation of PRMT1, a histone arginine methyltransferase, by sodium propionate induces cell apoptosis in colon cancer

Ryu,Tae   Young; Kim,Kwangkho; Son,Mi-Young; Min,Jeong-Ki; Kim,Janghwan; Han,Tae-Su; Kim,Dae-Soo; Cho,Hyun-Soo

doi:10.3892/or.2018.6938

Downregulation of PRMT1, a histone arginine methyltransferase, by sodium propionate induces cell apoptosis in colon cancer

Authors:
- Tae Young Ryu
- Kwangkho Kim
- Mi-Young Son
- Jeong-Ki Min
- Janghwan Kim
- Tae-Su Han
- Dae-Soo Kim
- Hyun-Soo Cho
View Affiliations

Affiliations: Korea Research Institute of Bioscience and Biotechnology, Daejeon 34141, Republic of Korea
Published online on: December 18, 2018 https://doi.org/10.3892/or.2018.6938
Pages: 1691-1699
Copyright: © Ryu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The microbiota and bacterial metabolites in the colon are regarded as alternative targets for colon cancer prevention and therapy. Among these metabolites, short-chain fatty acids (SCFAs) exhibit anticancer effects and suppress inflammation in the colon. However, the molecular mechanisms and target development of SCFAs require additional study. In the present study, using RNA-seq results from colon cancer samples derived from the Cancer Genome Atlas (TCGA) portal, overexpressed epigenetic modifiers were identified and RT-PCR and qRT-PCR analysis was performed to select target genes that responded to treatment with propionate in HCT116 cells. Downregulation of protein arginine methyltransferase 1 (PRMT1), a histone arginine methyltransferase, was observed after sodium propionate (SP) treatment. Moreover, phospho-array analysis demonstrated that the mTOR pathway was involved in propionate and siPRMT1 treatment, and regulation of this pathway was associated with apoptosis in HCT116 cells. The present study, to the best of our knowledge, was the first to demonstrate that PRMT1 levels were reduced by propionate treatment in HCT116 cells and that downregulation of PRMT1 induced cell apoptosis. Thus, this novel mechanism of sodium propionate treatment for colon cancer therapy may indicate more effective approaches, such as dietary therapy, for CRC patients.

View Figures

View References

1	Rea D, Coppola G, Palma G, Barbieri A, Luciano A, Del Prete P, Rossetti S, Berretta M, Facchini G, Perdonà S, et al: Microbiota effects on cancer: From risks to therapies. Oncotarget. 9:17915–17927. 2018. View Article : Google Scholar : PubMed/NCBI
2	Tan J, McKenzie C, Potamitis M, Thorburn AN, Mackay CR and Macia L: The role of short-chain fatty acids in health and disease. Adv Immunol. 121:91–119. 2014. View Article : Google Scholar : PubMed/NCBI
3	McNabney SM and Henagan TM: Short chain fatty acids in the colon and peripheral tissues: A focus on butyrate, colon cancer, obesity and insulin resistance. Nutrients. 9:13482017.doi: 10.3390/nu9121348. View Article : Google Scholar :
4	Davie JR: Inhibition of histone deacetylase activity by butyrate. J Nutr. 133 Suppl:2485S–2493S. 2003. View Article : Google Scholar : PubMed/NCBI
5	Hinnebusch BF, Meng S, Wu JT, Archer SY and Hodin RA: The effects of short-chain fatty acids on human colon cancer cell phenotype are associated with histone hyperacetylation. J Nutr. 132:1012–1017. 2002. View Article : Google Scholar : PubMed/NCBI
6	Ooi CC, Good NM, Williams DB, Lewanowitsch T, Cosgrove LJ, Lockett TJ and Head RJ: Structure-activity relationship of butyrate analogues on apoptosis, proliferation and histone deacetylase activity in HCT-116 human colorectal cancer cells. Clin Exp Pharmacol Physiol. 37:905–911. 2010. View Article : Google Scholar : PubMed/NCBI
7	Tian Y, Xu Q, Sun L, Ye Y and Ji G: Short-chain fatty acids administration is protective in colitis-associated colorectal cancer development. J Nutr Biochem. 57:103–109. 2018. View Article : Google Scholar : PubMed/NCBI
8	Fung KY, Brierley GV, Henderson S, Hoffmann P, McColl SR, Lockett T, Head R and Cosgrove L: Butyrate-induced apoptosis in HCT116 colorectal cancer cells includes induction of a cell stress response. J Proteome Res. 10:1860–1869. 2011. View Article : Google Scholar : PubMed/NCBI
9	Tang Y, Chen Y, Jiang H and Nie D: The role of short-chain fatty acids in orchestrating two types of programmed cell death in colon cancer. Autophagy. 7:235–237. 2011. View Article : Google Scholar : PubMed/NCBI
10	Yu DC, Bury JP, Tiernan J, Waby JS, Staton CA and Corfe BM: Short-chain fatty acid level and field cancerization show opposing associations with enteroendocrine cell number and neuropilin expression in patients with colorectal adenoma. Mol Cancer. 10:272011. View Article : Google Scholar : PubMed/NCBI
11	Bindels LB, Porporato PE, Ducastel S, Sboarina M, Neyrinck AM, Dewulf EM, Feron O, Lestavel S, Cani PD, Staels B, et al: Ffar2 expression regulates leukaemic cell growth in vivo. Br J Cancer. 117:1336–1340. 2017. View Article : Google Scholar : PubMed/NCBI
12	Kondo Y and Issa JP: Epigenetic changes in colorectal cancer. Cancer Metastasis Rev. 23:29–39. 2004. View Article : Google Scholar : PubMed/NCBI
13	Okugawa Y, Grady WM and Goel A: Epigenetic alterations in colorectal cancer: Emerging biomarkers. Gastroenterology. 149:1204–1225.e1212. 2015. View Article : Google Scholar : PubMed/NCBI
14	An W, Kim J and Roeder RG: Ordered cooperative functions of PRMT1, p300, and CARM1 in transcriptional activation by p53. Cell. 117:735–748. 2004. View Article : Google Scholar : PubMed/NCBI
15	Ryu JW, Kim SK, Son MY, Jeon SJ, Oh JH, Lim JH, Cho S, Jung CR, Hamamoto R, Kim DS, et al: Novel prognostic marker PRMT1 regulates cell growth via downregulation of CDKN1A in HCC. Oncotarget. 8:115444–115455. 2017. View Article : Google Scholar : PubMed/NCBI
16	Liao HW, Hsu JM, Xia W, Wang HL, Wang YN, Chang WC, Arold ST, Chou CK, Tsou PH, Yamaguchi H, et al: PRMT1-mediated methylation of the EGF receptor regulates signaling and cetuximab response. J Clin Invest. 125:4529–4543. 2015. View Article : Google Scholar : PubMed/NCBI
17	Tan CP and Nakielny S: Control of the DNA methylation system component MBD2 by protein arginine methylation. Mol Cell Biol. 26:7224–7235. 2006. View Article : Google Scholar : PubMed/NCBI
18	Kim SK, Kim K, Ryu JW, Ryu TY, Lim JH, Oh JH, Min JK, Jung CR, Hamamoto R, Son MY, et al: The novel prognostic marker, EHMT2, is involved in cell proliferation via HSPD1 regulation in breast cancer. Int J Oncol. 54:65–76. 2019.PubMed/NCBI
19	Kim K, Son MY, Jung CR, Kim DS and Cho HS: EHMT2 is a metastasis regulator in breast cancer. Biochem Biophys Res Commun. 496:758–762. 2018. View Article : Google Scholar : PubMed/NCBI
20	Kim DS, Ryu JW, Son MY, Oh JH, Chung KS, Lee S, Lee JJ, Ahn JH, Min JS, Ahn J, et al: A liver-specific gene expression panel predicts the differentiation status of in vitro hepatocyte models. Hepatology. 66:1662–1674. 2017. View Article : Google Scholar : PubMed/NCBI
21	Son MY, Jung CR, Kim DS and Cho HS: Comparative in silico profiling of epigenetic modifiers in human tissues. Mol Biol Rep. 45:309–314. 2018. View Article : Google Scholar : PubMed/NCBI
22	Jung KB, Lee H, Son YS, Lee MO, Kim YD, Oh SJ, Kwon O, Cho S, Cho HS, Kim DS, et al: Interleukin-2 induces the in vitro maturation of human pluripotent stem cell-derived intestinal organoids. Nat Commun. 9:30392018. View Article : Google Scholar : PubMed/NCBI
23	Nebbioso A, Tambaro FP, Dell'Aversana C and Altucci L: Cancer epigenetics: Moving forward. PLoS Genet. 14:e10073622018. View Article : Google Scholar : PubMed/NCBI
24	Yoshimatsu M, Toyokawa G, Hayami S, Unoki M, Tsunoda T, Field HI, Kelly JD, Neal DE, Maehara Y, Ponder BA, et al: Dysregulation of PRMT1 and PRMT6, type I arginine methyltransferases, is involved in various types of human cancers. Int J Cancer. 128:562–573. 2011. View Article : Google Scholar : PubMed/NCBI
25	Kapral M, Wawszczyk J, Jesse K, Paul-Samojedny M, Kusmierz D and Weglarz L: Inositol hexaphosphate inhibits proliferation and induces apoptosis of colon cancer cells by suppressing the AKT/mTOR signaling pathway. Molecules. 22:16572017.doi: 10.3390/molecules22101657. View Article : Google Scholar :
26	Tang Y, Chen Y, Jiang H and Nie D: Short-chain fatty acids induced autophagy serves as an adaptive strategy for retarding mitochondria-mediated apoptotic cell death. Cell Death Differ. 18:602–618. 2011. View Article : Google Scholar : PubMed/NCBI
27	Chen J, Ding J, Wang Z, Zhu J, Wang X and Du J: Identification of downstream metastasis-associated target genes regulated by LSD1 in colon cancer cells. Oncotarget. 8:19609–19630. 2017.PubMed/NCBI
28	Luo CW, Wang JY, Hung WC, Peng G, Tsai YL, Chang TM, Chai CY, Lin CH and Pan MR: G9a governs colon cancer stem cell phenotype and chemoradioresistance through PP2A-RPA axis-mediated DNA damage response. Radiother Oncol. 124:395–402. 2017. View Article : Google Scholar : PubMed/NCBI
29	Sarris ME, Moulos P, Haroniti A, Giakountis A and Talianidis I: Smyd3 is a transcriptional potentiator of multiple cancer-promoting genes and required for liver and colon cancer development. Cancer Cell. 29:354–366. 2016. View Article : Google Scholar : PubMed/NCBI
30	Yamamoto I, Nosho K, Kanno S, Igarashi H, Kurihara H, Ishigami K, Ishiguro K, Mitsuhashi K, Maruyama R, Koide H, et al: EZH2 expression is a prognostic biomarker in patients with colorectal cancer treated with anti-EGFR therapeutics. Oncotarget. 8:17810–17818. 2017. View Article : Google Scholar : PubMed/NCBI
31	Mathioudaki K, Papadokostopoulou A, Scorilas A, Xynopoulos D, Agnanti N and Talieri M: The PRMT1 gene expression pattern in colon cancer. Br J Cancer. 99:2094–2099. 2008. View Article : Google Scholar : PubMed/NCBI
32	Hu H, Qian K, Ho MC and Zheng YG: Small molecule inhibitors of rotein arginine methyltransferases. Expert Opin Investig Drugs. 25:335–358. 2016. View Article : Google Scholar : PubMed/NCBI
33	Park J, Kim M, Kang SG, Jannasch AH, Cooper B, Patterson J and Kim CH: Short-chain fatty acids induce both effector and regulatory T cells by suppression of histone deacetylases and regulation of the mTOR-S6K pathway. Mucosal Immunol. 8:80–93. 2015. View Article : Google Scholar : PubMed/NCBI
34	Pan P, Oshima K, Huang YW, Agle KA, Drobyski WR, Chen X, Zhang J, Yearsley MM, Yu J and Wang LS: Loss of FFAR2 promotes colon cancer by epigenetic dysregulation of inflammation suppressors. Int J Cancer. 143:886–896. 2018. View Article : Google Scholar : PubMed/NCBI